DE68925278T2 - Hemmung von htlv-iii durch exogene oligonukleotide - Google Patents

Hemmung von htlv-iii durch exogene oligonukleotide

Info

Publication number
DE68925278T2
DE68925278T2 DE68925278T DE68925278T DE68925278T2 DE 68925278 T2 DE68925278 T2 DE 68925278T2 DE 68925278 T DE68925278 T DE 68925278T DE 68925278 T DE68925278 T DE 68925278T DE 68925278 T2 DE68925278 T2 DE 68925278T2
Authority
DE
Germany
Prior art keywords
htlv
iii
inhibition
exogene
oligonucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68925278T
Other languages
English (en)
Other versions
DE68925278D1 (de
Inventor
John Goodchild
Paul Zamecnik
Sudhir Agrawal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Worcester Foundation for Biomedical Research
Original Assignee
Worcester Foundation for Biomedical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Worcester Foundation for Biomedical Research filed Critical Worcester Foundation for Biomedical Research
Publication of DE68925278D1 publication Critical patent/DE68925278D1/de
Application granted granted Critical
Publication of DE68925278T2 publication Critical patent/DE68925278T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C12N15/1132—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses against retroviridae, e.g. HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE68925278T 1988-02-26 1989-02-24 Hemmung von htlv-iii durch exogene oligonukleotide Expired - Fee Related DE68925278T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16057488A 1988-02-26 1988-02-26
PCT/US1989/000752 WO1989008146A1 (en) 1988-02-26 1989-02-24 Inhibition of htlv-iii by exogenous oligonucleotides

Publications (2)

Publication Number Publication Date
DE68925278D1 DE68925278D1 (de) 1996-02-08
DE68925278T2 true DE68925278T2 (de) 1996-09-19

Family

ID=22577455

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68925278T Expired - Fee Related DE68925278T2 (de) 1988-02-26 1989-02-24 Hemmung von htlv-iii durch exogene oligonukleotide

Country Status (6)

Country Link
EP (1) EP0402402B1 (de)
JP (1) JPH04501052A (de)
AT (1) ATE132190T1 (de)
AU (1) AU636573B2 (de)
DE (1) DE68925278T2 (de)
WO (1) WO1989008146A1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2029273A1 (en) 1989-12-04 1991-06-05 Christine L. Brakel Modified nucleotide compounds
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
EP0656942A1 (de) * 1990-09-21 1995-06-14 University Of Maryland Zusammensetzungen und verfahren für die inhibition von wachstum oder replikation von viren
JPH06504429A (ja) * 1990-10-09 1994-05-26 ネクスター・フアーマシユーテイカルズ・インコーポレイテツド ウイルス複製の阻害
EP0558749A1 (de) * 1990-11-20 1993-09-08 Sankyo Company Limited Antisense-nukleinsäurederivate
AU655279B2 (en) * 1991-04-05 1994-12-15 Edison Animal Biotechnology Center Retrovirus inhibition with antisense nucleic acids complementary to packaging sequences
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
US5332814A (en) * 1991-11-12 1994-07-26 Ciba-Geigy Corporation Process for the preparation of carbacyclic nucleosides, and intermediates
IL101600A (en) * 1992-04-15 2000-02-29 Yissum Res Dev Co Synthetic partially phosphorothioated antisense oligodeoxynucleotides and pharmaceutical compositions containing them
EP0577558A2 (de) * 1992-07-01 1994-01-05 Ciba-Geigy Ag Carbocyclische Nukleoside mit bicyclischen Ringen, Oligonukleotide daraus, Verfahren zu deren Herstellung, deren Verwendung und Zwischenproduckte
RU95104940A (ru) * 1992-07-27 1997-01-10 Хайбрайдон Способ введения в олигонуклеотид алкилфосфонотиоатной или арилфосфонотиоатной межнуклеотидной связи, способ получения олигонуклеотида, олигонуклеотиды, способ ингибирования генной экспрессии, способ лечения
JPH08504570A (ja) * 1992-10-05 1996-05-21 ハイブライドン インコーポレイテッド 治療用抗ｈｉｖオリゴヌクレオチドと薬剤
ES2128535T3 (es) * 1993-05-12 1999-05-16 Novartis Ag Nucleosidos y oligonucleotidos con grupos 2'-eter.
US5840497A (en) * 1993-06-11 1998-11-24 The Commonwealth Of Australia Commonwealth Scientific And Industrial Research Organization Method for specific silencing of genes by DNA methylation
JP2798305B2 (ja) * 1993-06-23 1998-09-17 ジェネシス ファーマ インコーポレイテッド アンチセンスオリゴヌクレオチドおよびヒト免疫不全ウイルス感染におけるその使用
DE4338704A1 (de) * 1993-11-12 1995-05-18 Hoechst Ag Stabilisierte Oligonucleotide und deren Verwendung
US6066447A (en) * 1994-01-26 2000-05-23 Novartis Corporation Modified oligonucleotides
DE59510742D1 (de) * 1994-04-27 2003-08-14 Novartis Ag Nukleoside und Oligonukleotide mit 2'-Ethergruppen
AU2604995A (en) * 1994-06-01 1995-12-21 Hybridon, Inc. Branched oligonucleotides as pathogen-inhibitory agents
GB9415129D0 (en) * 1994-07-27 1994-09-14 Lynxvale Ltd Oligonucleotides and their use
DE4427219A1 (de) * 1994-08-01 1996-02-08 Max Planck Gesellschaft Nukleinsäure zur Initiation der Aktivität von RNase H bzw. reverser Transkriptase
PT778844E (pt) * 1994-09-02 2003-04-30 Novartis Ag Complexos funcionais de metais de terpiridina processos para a sua preparacao e conjugados oligonucleotideos com complexos de metais de terpiridina
GB9604669D0 (en) 1996-03-05 1996-05-01 Ciba Geigy Ag Chemical compounds
US6776986B1 (en) 1996-06-06 2004-08-17 Novartis Ag Inhibition of HIV-1 replication by antisense RNA expression
DE19739956C1 (de) * 1997-09-11 1998-07-02 Horst Prof Dr Domdey tRNA-Primer, seine Herstellung und Verwendung zur Inhibierung der reversen Transkriptase
GB0012497D0 (en) * 2000-05-23 2000-07-12 Syngenix Ltd Antiviral therapy
EP1627563A1 (de) 2004-08-10 2006-02-22 Academisch Medisch Centrum bij de Universiteit van Amsterdam Verfahren und Mittel zur Herstellung einer stabilisierten Zelle
EP1647595A1 (de) * 2004-10-15 2006-04-19 Academisch Medisch Centrum bij de Universiteit van Amsterdam Nukleinsäuren gegen Viren, insbesondere gegen HIV
USRE49583E1 (en) 2005-11-17 2023-07-18 Tet Systems Gmbh & Co. Kg Inducible expression systems
ES2366227T3 (es) 2005-11-17 2011-10-18 TET Systems GmbH & Co. KG Sistemas de expresión inducibles.
ES2444465T5 (es) 2005-12-09 2023-11-30 Academisch Medisch Centrum Bij De Univ Van Amsterdam Medios y procedimientos para influenciar la estabilidad de las células productoras de anticuerpos
US9005974B2 (en) 2005-12-09 2015-04-14 Academish Medisch Centrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
SI2056845T1 (en) 2006-08-08 2018-02-28 Rheinische Friedrich-Wilhelms-Universitaet Bonn STRUCTURE AND USE 5 'PHOSPHATE OF OLIGONUCLEOTES
US9738680B2 (en) 2008-05-21 2017-08-22 Rheinische Friedrich-Wilhelms-Universität Bonn 5′ triphosphate oligonucleotide with blunt end and uses thereof
DK2454283T3 (en) 2009-07-15 2018-05-07 Aimm Therapeutics Bv METHODS AND PROCEDURES FOR MANUFACTURING HIGH EFFICIENCY ANTIBODIES
CN103429615B (zh) 2010-12-02 2018-03-16 埃姆医疗有限公司 用于生产高亲和力抗体的方式和方法
EP2508530A1 (de) 2011-03-28 2012-10-10 Rheinische Friedrich-Wilhelms-Universität Bonn Reinigung von triphosphorylierten Oligonucleotiden mit Einfang-Tags
EP2712870A1 (de) 2012-09-27 2014-04-02 Rheinische Friedrich-Wilhelms-Universität Bonn Neuartige RIG-I-Liganden und Herstellungsverfahren dafür
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3650756T2 (de) * 1985-03-21 2001-10-04 Cornell Res Foundation Inc Vom parasit abgeleiteter widerstand
EP0252940A4 (de) * 1985-12-05 1989-07-27 Hutchinson Fred Cancer Res Antisense-rna zur behandlung von retroviralen krankheiten.
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5110802A (en) * 1987-07-14 1992-05-05 City Of Hope Oligonucleotide phosphonates and method of inhibiting a human immunodeficiency virus in vitro utilizing said oligonucleotide phosphonates
ZA902912B (en) * 1989-04-21 1991-01-30 Cornell Res Foundation Inc Method of inhibiting induction of latent or chronic viral infection

Also Published As

Publication number Publication date
ATE132190T1 (de) 1996-01-15
JPH04501052A (ja) 1992-02-27
EP0402402A1 (de) 1990-12-19
AU636573B2 (en) 1993-05-06
AU4072089A (en) 1989-09-22
EP0402402B1 (de) 1995-12-27
WO1989008146A1 (en) 1989-09-08
DE68925278D1 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
DE68925278D1 (de) Hemmung von htlv-iii durch exogene oligonukleotide
DE3750615T2 (de) Hemmung von htlv-iii durch exogene oligonukleotide.
ATE154029T1 (de) 7-deazapurin modifizierte oligonukleotide
FI925103A (fi) Antisense-inhibitorer av humant immunbristvirus
ATE167803T1 (de) Hemmung der replikation des influenza-virus durch oligonukleotide
AU8771398A (en) Novel hiv-specific synthetic oligonucleotides and methods of their use
BR9206156A (pt) Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS
NO901213D0 (no) Genetiske enheter for inhibering av funksjonen til rna.
DK0832211T3 (da) Oligonucleotider, der er specifikke for hepatitis B-virus.
ATE163973T1 (de) Antisense oligonukleotidhemmung von papillomavirus
DK0775745T3 (da) Cathepsin G-inhiberende aptamerer
Srivastava Inhibition of oncorna virus and cellular DNA polymerases by natural and synthetic polynucleotides
FR2639830B1 (fr) Composition antivirale et ses applications
EP1331267A3 (de) Spezifische Oligonukleotide für Hepatitis C-Virus
KR950023404A (ko) 5-히드록시메틸-2-푸르푸랄을 함유하는 비(b)형 간염 치료제

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: WORCESTER FOUNDATION FOR BIOMEDICAL RESEARCH, INC.

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee